

AHCC Trials Group

Newsletter May 2013

Contents

Page 1

The Buzz

- About the AHCC Trials Group

Page 1

Happenings

- AHCC03 Paper Published in World Journal of Surgery

Page 2-3

Highlights – AHCC06

- Study Status
- Site Initiation Visits

Page 4

Announcements

- SCRI – who's who?

AHCC Trials Group

Group Chair:

Prof Soo Khee Chee

Protocol Chair, AHCC06:

Prof Pierce Chow

Trials Group Website:

<http://www.scri.edu.sg/index.php/ahcc-trials-group>

The Buzz

About the AHCC Trials Group

Greetings to all members of the AHCC Trials Group!

The AHCC Trials Group has grown from its humble beginnings since 1997 into a network that has launched 6 multi-centre randomised controlled trials, involving 15 countries across the Asia Pacific, and encompassing a community of over 70 principal investigators and clinicians from major medical centres.

Over the years, the group's aims remain to conduct preventive and therapeutic trials in Hepatocellular Carcinoma (HCC), carry out basic and translational research in this field, and develop training and educational programs pertaining to HCC. Leveraging on shared vision and the mutual support of members, the group is focused on new and promising scientific collaborations that investigate new efficacious therapies for HCC patients. New trials are in the pipeline and the group is in discussion with biotechnology and pharmaceutical groups with shared views of future collaborations.

The AHCC Trials Group had a most memorable 5th General Meeting on the 6th February 2010. We certainly look forward to the next General Meeting, which is expected to be held in the beginning of the 2014!

Happenings

AHCC03: Randomised Trial of Adjuvant Hepatic Intra-Arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma



Published in World Journal of Surgery on 6 March 2013!

Adjuvant Hepatic Intra-arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma: A Prospective Randomized Trial. *World J Surg.* 2013: 1-6.

Trial Coordinating Centre:



SCIENTIFIC COLLABORATION FOR RESEARCH INNOVATION



AHCC06 (SIRveNIB)

Phase III Multi-Centre Open-Label Randomized Control Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma

Protocol Chair:

Prof Pierce Chow, SingHealth and Duke-NUS

Study Status:

As of 1 May 2013, there are 27 actively recruiting trial sites. Two new centres, Chulabhorn Hospital, Bangkok and Davao Doctors Hospital, Philippines were initiated in Feb 2013, and we have 179 patients (49% of target) enrolled to date.

The trial's first scheduled Interim Analysis will take place on 22 May 2013. The Interim Analysis by the independent Data Monitoring Committee (DMC) will review the progress, safety and efficacy of the trial, and make recommendations for the future direction and conduct of the trial.

The trials group is honoured and privileged to have experienced trialists Dr Thomas Leung (Associate Director and Honorary Consultant from Hong Kong Sanatorium and Hospital) as the Chairman of the DMC, Prof David Machin (Emeritus Professor of Clinical Statistics, University of Leicester and Emeritus Professor of Clinical Trials Research, University of Sheffield, United Kingdom), and Dr Bruno Sangro (Director of the Hepatology Unit, Department of Internal Medicine at the University Hospital of Navarra, Spain) as members of the DMC.

The Interim Analysis is an important milestone for the trial and the study team is looking forward to the meeting.

For more details of the AHCC06 investigators, visit <http://www.scri.edu.sg/index.php/clinical-trials>

Participating Centres:

Brunei:

- RIPAS Hospital

Hong Kong:

- Queen Mary Hospital

Indonesia:

- University of Indonesia

- Sanglah General Hospital

Korea:

- Asan Medical Center

- Korea Anam University Hospital

- Seoul National University Bundang Hospital

- Seoul St. Mary's Hospital

- Severance Hospital

- St. Vincent's Hospital

Malaysia:

- Penang Adventist Hospital

Mongolia:

- National Cancer Center

Myanmar:

- Yangon GI & Liver Centre

New Zealand:

- Auckland City Hospital

Philippines:

- Makati Medical Center

- St. Luke's Medical Center

- The Medical City

- Davao Doctors Hospital

Singapore:

- Changi General Hospital

- Khoo Teck Puat Hospital

- National Cancer Centre

- National University Hospital

- Singapore General Hospital

Taiwan:

- National Taiwan University Hospital

- Chang Gung Memorial Hospital, LK

- Taipei Veterans General Hospital

- China Medical University Hospital

- Kaohsiung Chang Gung Memorial Hospital

Thailand:

- Chulabhorn Hospital



Dr Brian Goh (member of the Steering Committee) giving an introduction of the AHCC06 trial to Davao Doctors Hospital, Philippines.

Site Initiation Visits

In the month of February 2013, the study team conducted site initiation visits at Chulabhorn Hospital, Bangkok and Davao Doctors Hospital, Philippines.

Chulabhorn Hospital, Bangkok

The site initiation visit to Chulabhorn Hospital, Bangkok was conducted on 8 Feb 2013. The site is led by Dr Chanisa Chotipanich, a nuclear medicine physician at the National Cyclotron and PET Centre.

The site has randomised 2 patients in March and April 2013.

The study team is pleased with the readiness of the site and confident that the collaboration will be a success.

Site PI: A/Prof Chanisa Chotipanich



From left, Mr Bancha Chiwasantikan, Prof Pierce Chow (Protocol Chair), Dr Chanisa Chotipanich (Site PI), Sophie Moss (PM, SCRI), Dr Chetsadaporn Promteangtrong (Site Co-I), Sirinsuda Somboon (Site Study Co-ordinator), Mr Paramest Wongsu (Site Study Co-ordinator) and Mr Xia Yu (CRA, SCRI).

Davao Doctors Hospital, Philippines



From left, Ms Julienine Cayunda (Site Oncology Nurse), Ms Anna Yap (Site Oncology Research Nurse), Dr Rolley Lobo (Site PI), Dr Frances Tongcos (Site Co-I), Ms Sandra Hsing (CRA, SCRI) and Dr Brian Goh (member of the Steering Committee).


Site PI: Dr Rolley Lobo

Dr Brian Goh led the study team in the site initiation visit at Davao Doctors Hospital on 6 to 7 Feb 2013.

The Davao Doctors Hospital is the largest and most modern hospital in Southern Philippines and a regional leader in liver diseases. The study team looks forward to working with the site!



SCRI – who's who



Ms Cindy Seow

We warmly welcome Cindy to the AHCC06 study team!

Cindy Seow joined SCRI in February 2013 as Clinical Research Associate. She will be in charge of the Mongolian site in the AHCC06 trial.

Prior to joining SCRI, she was a Clinical Research Coordinator at the National Cancer Centre, Singapore and has 2 years of experience in oncology trials.

The study team is looking forward to working with Cindy. Welcome aboard!

If you are thinking about a new study concept and wish to collaborate with us, do contact the Network Secretariat for more information.



Contact Details

Network Secretariat:

- Ms Lynette Lai lynette.lai.s.h@sgh.com.sg
DID: (65) 6576 2151
Fax: (65) 6220 9323
- Ms Nicole Kong nicole.kong.h.y@sgh.com.sg
DID: (65) 6326 6450
Fax: (65) 6220 9323

Mailing Address: 31 Biopolis Way Nanos #02-01 Singapore 138669



Acknowledgements:

National Medical Research Council Singapore, SingHealth Foundation, National Cancer Center Singapore, PsiOncology Pte Ltd, Sirtex Medical and Bayer Pharmaceutical for support of our clinical trials, past and present